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Abstract
Membranous Ki-67 staining with the MIB-1 antibody has been described in hyalinising trabecular adenomas of the thyroid and
sclerosing haemangiomas of the lung. Its relatively rare occurrence in breast tumours has also been documented. The aim of the
present study was to assess the rate of any membranousMIB-1 staining in breast specimens. The staining was performed at room
temperature with 1:100 dilution of the antibody. One hundred four core needle biopsies and 41 operative specimens were
analysed. Membranous staining was noted in 36/144 invasive carcinomas, 20/42 in situ carcinomas and 46/99 cases of
peritumoural benign/normal breast epithelium. Most often, it presented as focal and partial polarised luminal membranous
staining although complete circumferential staining also occurred, and membranous labelling was sometimes accompanied by
cytoplasmic staining, too. In a few cases tested, greater dilution of the primary antibody did not abolish the membranous staining,
which was absent with the SP6 monoclonal Ki-67 antibody. The membranous staining of invasive tumours showed no associ-
ation with histological grade, lumen formation, oestrogen or progesterone receptor status or the Ki-67 nuclear labelling. In
contrast, it was associated with a HER2-positive status, although it occurred in all molecular subtypes approached by immuno-
histochemistry. The background of this membranous staining remains elusive. It is unlikely to represent an artefact. At least
partial sharing of an epitope of the nuclear Ki-67 protein with an unidentified membranous protein and some functional
differences between membranous staining producing tumours and tumours lacking this pattern of staining may both contribute
to some extent.
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Introduction
Proliferation of malignant tumours is closely related to their
progression and prognosis. Ki-67, as detected by immunohis-
tochemistry (IHC), is widely used as a proliferation marker
because it is expressed through the cell cycle, except the G0
phase [1]. Several studies have proven its prognostic value in
breast cancer [2, 3], and this marker also made its way to
influence therapeutic decisions [4]. The distinction between
luminal A-like and luminal B-like breast cancers by the
IHC-based surrogate classification is also influenced by the
Ki-67 proliferation rate, although the cut-off value for the
discrimination has changed time to time [5–7]. There are
many issues which lack standardization in the context of
Ki-67 IHC evaluation, and these include the antibodies
used as well as the methods of assessment and quantifica-
tion. Therefore, an international panel set up and made rec-
ommendations in order to harmonise the practice of Ki-67
evaluation in breast cancer [8]. These recommendations
suggest that, optimally, the MIB-1 mouse monoclonal anti-
body should be used as this is the most studied and most
widely applied one [8]. Despite these recommendations,
national guidelines vary, and the reproducibility of the Ki-
67 labelling index as a proliferation marker seems less than
optimal to base treatment decisions on it [9]. In Hungary,
Ki-67 immunostaining of breast carcinomas has become
more and more commonly asked for by the oncological
community, and this staining was included in a recent con-
sensus recommendation on the histopathological work-up
of breast cancers [10].
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Ki-67 staining is a nuclear one, of which the intensity
varies during the cell cycle, being the highest in the M phase
and much lower in G1 and S phases [3]. A membranous (and
cytoplasmic) staining pattern has also been recognised as one
of differential diagnostic values: this is seen in hyalinising
trabecular tumour (HTT) of the thyroid gland but not in pap-
illary thyroid carcinoma to which this HTT resembles [11].
Another tumour, which has been described to show membra-
nous (and cytoplasmic) staining for Ki-67 as opposed to lung
cancer, is pulmonary sclerosing haemangioma [12]. Although
Leonardo et al. were unable to reproduce this staining pattern
in their eight cases of pulmonary sclerosing haemangiomas,
they observed the membranous staining on six HTTs, four
invasive breast cancers and single cases of sarcomatoid meso-
thelioma and oncocytoma, respectively [13]. The reported
immunolabelling was rather diffuse and presented
circumferentially on the outer surface of the cells and was
occasionally associated with cytoplasmic staining, too.
These authors also demonstrated that the membranous stain-
ing pattern is typical for the MIB-1 clone (both from
DAKOCytomation, Glostrup, Denmark, 1:300 dilution and
Immunotech, Marseille, France, 1:300 dilution) at room tem-
perature and is not seen with other antibodies (7B11, Zymed,
San Francisco, 1:200 dilution; KIS5, DAKOCytomation,
Glostrup, Denmark, 1:300 dilution; KI88, Biogenex, San
Ramon, kit dilution) or at a higher temperature (37 °C) [13].
On the contrary, some authors have found identical staining
intensity and ratio at room temperature and at 37 °C [14].
Although reported as early as 2007 [13], membranous
staining of breast tumours is not widely recognised, and when
encountered for the first time, it may give rise to the suspicion
of a technical failure. In this study, membranous Ki-67 stain-
ing was systematically evaluated along with the nuclear stain-
ing for which the IHC reaction was done, and was noted in a
surprisingly high proportion of cases.
Materials and methods
According to the International Ki-67 in Breast Cancer
Working Group recommendations [8], no tissue microarrays
were used; the immunostainings for Ki-67 were performed on
core needle biopsy (CNB) specimens or operative specimens,
in 2017. All tissues were fixed in buffered formalin and em-
bedded in paraffin. During the period involved, two different
batches of the MIB-1 monoclonal antibody (Dako, Glostrup,
Denmark, Catalogue number: M7240) were used in sequence,
at a dilution of 1:100 (incubation at room temperature for 1 h)
after 45 min of heat-induced epitope retrieval at 98 °C in pH 6
citrate buffer. The author assessed Ki-67 nuclear labelling by
estimation on the whole tumour area seen on the slide [15] and
rounding off the values [16], therefore reducing the values to a
limited possibilities (i.e. 1, 2, 3, 5, 10, 15, 20, 25, 30, 40, 50,
60, 70, 80 or 90%). Additionally, as part of the routine work-
up, the oestrogen receptor (6F11, Leica Biosystems,
Novocastra, Newcastle, UK), progesterone receptor (Pgr312,
Leica Biosystems, Novocastra, Newcastle, UK) and human
epidermal growth factor receptor-2 (HER2) statuses (4B5,
Roche-Ventana, Tucson, AZ, USA) were also determined.
The evaluation of these stainings followed the Hungarian
guidelines [10], which themselves follow the American
Society of Clinical Oncology [17] and United Kingdom
guidelines [18] for the relevant testings. Specimens with a
2+ IHC score for HER2 were tested by chromogenic in situ
hybridisation (Zytodot 2C SPEC ERBB2/CEN 17 kit,
ZytoVision, Bremerhaven, Germany).
Additionally, a pair of cases were stained with the MIB-1
antibody at dilutions of 1:200 and 1:400 and with the SP6
(Histopathology Ltd., Pécs, Hungary) and MM1 (Biocare,
Concord, CA, USA) antibodies, too.
Ki-67 membranous staining was screened at medium pow-
er (× 100), and the slides were scrutinised for any membra-
nous staining in invasive and in situ carcinomas as well as
normal breast epithelium or benign lesion when present on
the slide used for the evaluation. The policy of interpreting
any membranous staining as positive was chosen in parallel
with the interpretation of nuclear Ki-67 labelling, where any
intensity is taken as positive and reflecting the cell being in the
cell cycle [8]. One slide was used in each case, and this gen-
erally included either three 1-mm-large cores for biopsy sam-
ples or a full-face cut-surface from a standard tissue block for
operative specimens.
Statistical analyses were performedwith VassarStats (avail-
able at http://vassarstats.net; Richard Lowry, Vassar College,
Poughkeepsie, NY; accessed 05–10 January 2018). The 95%
confidence interval (CI) of proportions was calculated with a
correction for continuity. Categorical variables were analysed
for an association with membranous Ki-67 staining with the
chi-square test (according to Yates, with correction for conti-
nuity); when the number of elements was too low, the Fisher
exact test was used instead, with two-sided p values < 0.05
considered significant.
No ethical approval was deemed necessary for this non-
interventional study requiring no patient identification or data,
using only slides which were available as part of the routine
work-up.
Results
Altogether, 145 specimens of 144 patients were assessed; one
patient had two tumours sampled by CNB; 135 tumours were
primary carcinomas, nine were recurrences and one tumour
tested was an adenomyoepithelioma. The material investigat-
ed consisted of 104 CNB samples and 41 resection samples.
There were no differences between the proportion of either
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invasive or in situ carcinomas or normal/benign epithelium
demonstrating membranous staining in the two types of
specimen.
Membranous staining was identified in 36 invasive carci-
nomas. It was most often luminal (n = 20), sometimes circum-
ferential over the luminal surface even if not complete (n = 9)
or demonstrated the combination of these two patterns (n = 7).
Some cancers showed luminal (Bmembranous^) labelling in
intracytoplasmic vacuoles too, and cytoplasmic staining also
occurred in a minority of the tumours (Fig. 1).
The relation of any membranous Ki-67 staining and differ-
ent aspects of the carcinomas investigated is shown in Table 1.
No association was found with pTand pN categories (as com-
ponents of the anatomical stage [19]). Lobular carcinomas
showed this pattern much less commonly (1/19; 5.3%, 95%
CI 0.3–28.1%) than ductal (no special type, NST) and tubular
carcinomas (35/123, 28.5%; 95% CI 20.9–37.4%) (Table 1),
and the difference in staining between lobular and non-lobular
carcinomas was also significant (p = 0.044, Fisher’s exact
test). The lobular carcinoma demonstrating a membranous
staining showed this feature focally around the intracellular
vacuoles. The single cases of tubulolobular, mucinous, inva-
sive micropapillary and invasive solid papillary carcinomas
showed only nuclear Ki-67 positivity, although one NST tu-
mour, with less than 50% micropapillary component, showed
the characteristic inside-out polarised membranous staining
typical of this histological type, which is generally seen with
the MUC1 and some other antibodies [20] (Fig. 1b). The
observation that most of the membranous staining was lumi-
nal suggested that lumen formation might be a feature
influencing the phenomenon of membranous labelling.
However, the highest proportion of membranous positivity
occurred with a tubule formation grading score of 2, and nei-
ther the score for tubule formation nor the histological grade
was associated with membranous Ki-67 staining. There was
also no association between membranous Ki-67 staining and
ER or PR status and the Ki-67 (nuclear) labelling index (either
with a cut-off of 15% or with one of 20%), but a significant
association was found with the HER2 status and molecular
subtypes approached by an IHC-based surrogate classifica-
tion. HER2-positive tumours showed the highest labelling,
but membranous staining was seen in all types of carcinomas
(Table 1).
19/40 (47.5%, 95% CI 31.8–63.6%) DCIS, 1/2 (50.0%,
95% CI 2.7–97.3%) LCIS and 46/99 (46.5%, 95% CI 36.5–
56.7%) associated benign lesions or normal breast tissue
showed membranous labelling with Ki-67. In 10 DCIS and
33 cases of normal/benign epithelial structures, these membra-
nous positivities were seen without membranous staining of
the invasive tumour. Less than half (71/145, 49.0%; 95% CI
40.6–57.4%) of the assessed slides were completely devoid of
membranous staining. Forty-two slides included both in situ
and invasive carcinoma, and membranous staining was seen
in both components in 11 (26.2%; 95% CI 14.4–42.3%).
Thirty-one of these slides also included at least some normal
breast parenchyma or benign lesions, and membranous Ki-67
positivity was seen in all three components in 4 (12.9%; 95%
CI 4.2–30.8%).
Discussion
After the first description of four cases of breast cancer dem-
onstrating membranous MIB-1 labelling at room temperature
by Leonardo et al. [13], a larger series was published including
322 breast carcinomas, of which 26 (8%) showed membra-
nous (and cytoplasmic) staining with the Dako antibody at a
dilution of 1:50 at both room temperature and 37 °C [14]. Four
of these cases showed an apical/luminal type staining, where-
as 22 were reported to have a cytoplasmic positivity with
accentuation on the cytoplasmic membrane. Although diffuse
and strong membranous positivity was more common, focal
and weak positivity also occurred. As no cut-off staining pro-
portion or intensity was mentioned, it is most likely that any
staining was considered positive, similarly to the present
study. The presence of membranous staining was correlated
with histological grade 3, an ER-negative and a HER2-
positive status, although membranous staining failed to be
an independent marker of poor prognosis in a multivariate
model [14]. Another study with 27/136 (20%) membranous/
cytoplasmic staining rate of either primary breast and/or met-
astatic nodal carcinomas also found a similar association with
the ER status [21].
In contrast to the tissue microarray-based study
summarised above [14], membranous MIB-1 staining oc-
curred in the majority of the cases reported in the present
article. It was not limited to invasive carcinomas but DCIS
and normal breast epithelium also showed this feature; the
staining of these latter two components did generally not
follow the staining of the invasive carcinoma on the same
slide. The membranous staining was generally focal, some-
times weak (Fig. 1h) or limited to a few cells (Fig. 1d) and
needed meticulous search for identification, but in other
cases, it was diffuse and strong, noticeable without search.
Another discrepancy from the previously cited study [14]
was the more commonly seen polarised luminal staining
rather than complete circumferential staining of the cells.
This pattern is reminiscent of the focal to diffuse CD10
membrane positivity seen in apocrine lesions [22]. An area
of micropapillary differentiation in an NST carcinoma (but
not in the single micropapillary carcinoma case) also dem-
onstrated the inside-out pattern of polarised membranous
staining which is typical of this histological type of cancer
with the MUC1 antibody [20]. The much higher rate of
positivity reported in this series may be related to the com-
monly focal nature of Ki-67 membranous staining, which
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may therefore be underestimated in tissue microarrays. The
method used here, scrutinizing the slides for even very focal
staining, can also have some role in the discrepancy.
The origin of such a membranous staining with an anti-
body detecting a nuclear antigen remains unresolved. Three
possible explanations have been proposed. First, an
artefactual nature was formulated, but all authors agree that
the pattern of staining with its crisp character and features
like the limitation of the staining to HTT and not to papil-
lary carcinomas in the thyroid is so much against an artefact
and that the two other possibilities are much likelier. Either
a cross-reacting or homologous epitope [11–13] or a func-
tional translocation of the antigen or its part [14] may play a
role in it.
Ki-67 is a large protein coded by MKI67 mapping to
10q26.2. The National Institutes of Health protein database
[23] contains two Homo sapiens-derived isoforms of the pro-
liferation marker protein Ki-67, which are 3256 and 2896
amino acids (AAs) long, respectively. These two proteins
share the 2896 AAs of the shorter isoform 2, but there are
360 consecutive AAs in addition in the primary structure of
the protein Binserted^ at AA position 136 in the longer isoform
1; i.e. isoform 2 lacks an in-frame exon in the 5′ coding region
as compared to isoform 1. It is unknown whether the isoforms
react differently with any of the antibodies (or especially the
MIB-1 antibody) used for the IHC detection of Ki-67 and
whether their existence can contribute to the membranous
localization of the reported staining. The fact that only MIB-
Fig. 1 Examples of MIB-1
staining patterns seen in parallel
with the expected nuclear
staining. a Polarised (luminal)
membranous staining of an NST
breast cancer demonstrating
minor areas of invasive
micropapillary carcinomas shown
in part b. bMicropapillary area of
the tumour shown in part a,
demonstrating a typical inside-out
pattern. c: Focal intracytoplasmic
vacuole Bmembranous^ staining
(arrows). d Minimal luminal
membranous staining (arrow)
requiring specific search for
detection. e DCIS demonstrating
luminal membranous staining, but
probably due to the plane of
sections, some cells also show a
circumferential membranous
labelling. f A tumour with focal
circumferential membranous
staining of some cells with or
without nuclear and/or
cytoplasmic staining. g Benign
cyst with circumferential luminal
staining and smaller gland with
focal luminal membranous
staining (arrow). hMinimal weak
focal luminal staining of a
cribriform low grade DCIS
(asterisk) (a, b, c, d and h ×40; e, f
and g ×70)
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Table 1 The relation of membranous Ki67 staining and histological parameters of the tumours
Membranous Ki67+ Membranous Ki67−
pT categories p = 0.896
Tx 11 38
T1mi, T1a, T1b 3 12
T1c 10 31
T2 10 22
T3, T4 2 5
pN categories p = 0.337
Nx 13 42
N0 13 45
N1 9 14
N2, N3 1 7
Histological type p = 0.071*
NST (ductal) 33 85
ILC 1 18
Other 2 5
Or p = 0.044*
NST (ductal) + tubular 35 88
ILC 1 18
Histological grade p = 0.383
1 10 21
2 11 46
3 14 39
Score for tubules p = 0.056
1 4 8
2 15 26
3 16 73
ER status p = 0.108
Positive 27 95
Negative 9 13
PR status p = 0.052
Positive 23 88
Negative 13 20
HER2 status p = 0.007
Positive 11 11
Negative 25 97
Ki67 p = 0.566
High (> 15%) 21 55
Low (≤ 15%) 15 53
Or p = 0.624
High (> 20%) 16 41
Low (≤ 20%) 20 67
IHC surrogate subtypes p = 0.030 (df = 4); p = 0.015 (df = 3)
TN 5 10
HER2 + (ER−) 4 3
HER2 + (ER+) 7 8
LUM B-like (> 15%) 7 37
LUM A-like (− 15%) 13 50
Or p = 0.021 (df = 4); p = 0.010 (df = 3)
TN 5 10
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1 gives the membranous reaction would be logically related to
a specific cross-reaction of the antigen recognizing Fab part of
this antibody (and not the others) with a membranous compo-
nent and the nuclear Ki-67 protein. The temperature-related
staining differences seem more difficult to explain, but may
be related to the alterations of the tertiary structure of the
antigen detected on the membrane. The nuclear and membra-
nous staining showed no association (Table 1), and there were
cells with either both or none of these staining patterns. The
focal nature of the membranous staining could suggest a spu-
rious reaction, but the fact that, often, the focal staining was
polarised to the luminal surface of the cell membrane and an
association with HER2 overexpression (see below) would be
against a false reaction. The scarcity of the related literature
and the data at hands do not allow a clear statement about the
origins of the membranous MIB staining in different tissues,
and the possible explanations remain hypothetical; the present
author prefers the cross-reaction of epitopes theory.
When five antibodies were compared, the membranous
staining was seen only with the MIB-1 antibodies from two
different sources, and three other antibodies failed to give this
staining in addition to the nuclear one [13]. In an independent
study, MIB-1 was compared with a fourth monoclonal anti-
body, BGX-Ki67 (Biogenex, Fremont, CA, USA; 1:75 dilu-
tion), and again, membranous staining was only seen with
MIB-1 [21]. The membranous/cytoplasmic staining with
MIB-1 did not vanish with any of three different antigen re-
trieval methods, two different detection systems and in either
of the two laboratories doing the staining [21]. Although the
aim of the present study was only the assessment of the prev-
alence of MIB-1 membranous staining in breast lesions and
normal structures, a pair of cases were evaluated with alterna-
tive stainings. The original dilution of the MIB-1 antibody
(1:100) was within the range proposed by the manufacturer
(1:75–1:150), but further dilutions (1:200 and 1:400) were
also used, and although there was a slight reduction in
membranous (and nuclear) staining, further dilution of the
primary antibody did not abolish the reaction. Two different
batches of MIB-1 were used during the period invested, and
membranous staining occurred with both. There was no mem-
branous staining with the SP6 rabbit monoclonal Ki-67 anti-
body (Fig. 2) and the MM1 mouse monoclonal antibody (not
shown). These results are in keeping with previous reports
[11–13]. Similarly to differences in nuclear labelling [24],
the antibodies are different in membranous labelling, too;
MIB-1 appears to be the only antibodywhere the membranous
(/cytoplasmic) pattern has been described. The differences in
staining and their characteristics listed above are very likely to
be related to the differences in the epitopes recognised by the
different antibodies, although the exact epitopes are not
known. The above data point to a specific MIB-1-antibody-
antigen reaction shared between the nuclear Ki-67 protein and
an unknown membranous epitope, which may or may not be
part of the Ki-67 molecule. Differences in qualitative (yes or
no) nuclear labelling are considered to reflect whether the cell
is in the cell cycle or not, whereas differences in quantitative
labelling (intensity of staining) are interpreted as differences in
different phases of the cell cycle. On the other hand, there are
many technical and probably biological issues whichmay also
influence the nuclear staining, which is antibody dependent
and demonstrates differences according to the antibody used
[24].
Similar qualitative and quantitative differences in membra-
nous (/cytoplasmic) MIB-1 staining are more difficult to ex-
plain and remain a mystery. Although the membranous Ki-67
staining has been related to Ba peculiar neoplastic phenotype^
[13], because the staining was mainly recognised in benign
and malignant tumours, the present results suggest that even
normal breast epithelium may display this pattern of Ki-67
labelling. Rare Bluminal border^ of normal thyroid follicles
and occasional alveolar side surface membrane Ki-67
immunopositivity were noted by the early descriptions of
Table 1 (continued)
Membranous Ki67+ Membranous Ki67−
HER2 + (ER−) 4 3
HER2 + (ER+) 7 8
LUM B-like (> 20%) 3 24
LUM A-like (− 20%) 17 63
DCIS p = 0.999
LG 3 3
IG 7 7
HG 8 10
df degree of freedom (4 with all categories together; 3 with HER2 positives taken as a single category), NST no special type, ILC invasive lobular
carcinoma, TN triple-negative,HER2+Human epidermal growth factor receptor 2-positive,ER+ oestrogen receptor-positive, LUMA luminal A, LUMB
luminal B, DCIS ductal carcinoma in situ, LG low grade, IG intermediate grade, HG high grade
*All p values are from chi-square test, except those labelled with an asterisk, where the Fisher exact test (two sided) was used
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membranous Ki-67 staining in HTT [11] and pulmonary scle-
rosing haemangiomas [12], respectively. While collecting the
material for this analysis, a bronchial biopsy demonstrating
focal luminal MIB-1 staining of bronchial glands and epithe-
lium was also identified (Fig. 3), reinforcing that the membra-
nous staining pattern is not restricted to neoplastic lesions, and
staining of the normal epithelium is not restricted to breast
tissues.
Only a few specimens demonstrated membranous staining
in all three compartments (normal/benign, in situ carcinoma
and invasive carcinoma), and matching positivity of the DCIS
and invasive component was only seen in about a quarter of
the cases. In a study documenting 27/136 cases with membra-
nous MIB-1 staining in either the primary or the nodal meta-
static breast carcinoma, about a half of the cases (n = 14) had
membranous staining at both sites [21]. The lack of a complete
match of membranous staining between in situ carcinoma,
invasive carcinoma and metastatic carcinoma may be related
to the focal nature of the membranous staining and to the fact
that less than the whole of the tumour was investigated.
However, it can also reflect that the membranous staining
has nothing to do with a Bgenuine^ feature or function of the
neoplastic (or normal) tissues. Contrasting with this last pos-
sibility, some functional differences have been noted between
tumours with and without membranous MIB-1 labelling.
An association between an ER-negative status and mem-
branous MIB-1 labelling was reported in two independent
studies [14, 21]. Although there seemed to be a higher propor-
tion of ER-negative carcinomas that demonstrated membra-
nous staining in this series, too (41 vs 22%), there was no
statistical difference in the rate of membranous staining of
ER-negative and ER-positive tumours (Table 1). In contrast,
HER2 positivity was associated with the membranous
staining, similarly to previous reports [14, 25]. The molecular
subtypes approached by IHC were also associated with the
membranous staining pattern, probably because of the com-
bined influences of the HER2 and ER statuses. In our study,
the MIB-1 nuclear labelling index showed no association with
membranous staining, and this was the case in a previous
Fig. 2 Alternative Ki67 stainings
tested in the study. Same area of a
tumour with MIB-1 membranous
staining at dilutions 1:100 (a),
1:200 (b) and 1:400 (c) lacking
this staining pattern with the SP6
antibody (d) (a–d ×40)
Fig. 3 Bronchial biopsy with luminal membranous staining of bronchial
glands and epithelium (a ×40; b ×70)
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study, too [14], but others have found a higher Ki-67 nuclear
labelling with an alternative antibody in cases with membra-
nous MIB-1 staining (BGX-Ki67) [21]. Interestingly, three
cases were found to have a membranous/cytoplasmic MIB-1
labelling without nuclear staining but a high nuclear labelling
with the alternative Ki-67 antibody used in parallel [21].
These data together would suggest the contribution of a bio-
logical factor as the explanation for the membranous MIB-1
labelling, which, however, would be difficult to consider be-
hind the membranous staining of normal breast epithelium.
Finally, it may be mentioned that diffuse and continuous
membranous staining has been observed as an artefact with
the SP6 antibody in a multiplexed immunofluorescent system,
but this was clearly due to the non-specific binding of the SP6
anti-Ki-67 antibody to the secondary antibody detecting HER2
on the membranes, and could be specifically blocked [26]. This
artefactual membranous staining has therefore nothing to do
with the MIB-1-related membranous staining, but highlights a
potential confounding factor that can step in while trying to
clarify the origin of the membranous MIB-1 labelling.
In summary, a relatively high proportion of breast speci-
mens have been reported to demonstrate at least focal mem-
branous labelling with the MIB-1 Ki-67 antibody. This stain-
ing pattern, along with nuclear labelling, was seen in both
normal/benign epithelium, in situ and invasive carcinomas.
Although membranous staining in carcinomas was associated
with HER2 positivity, it is difficult to explain why some tu-
mours show such membranous staining and others do not and
why some areas in a tumour show a membranous staining
while others do not.
Author contribution The author of the manuscript made substantial
contributions to the following:
- the conception/design of the work; the acquisition, analysis, interpreta-
tion of data for the work;
- drafting the work and/or revising it critically for important intellectual
content;
- final approval of the version submitted for publication; and
- agreement to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
Other contribution is acknowledged in the Funding section of the
manuscript.
Funding This study was partially funded by the National Research,
Development and Innovation Office grant GINOP-2.3.2-15-2016-00020.
Compliance with ethical standards
The author has consulted the journal policy regarding compliance with
ethical standards and state that accepted principles of ethical and profes-
sional conduct have been followed. The author includes information regard-
ing sources of funding and potential conflicts of interest (financial or non-
financial) (next section). Ethical approval and informed consent-related
information (waiver for this particular study) are summarised in the final
paragraph of the BMaterials and methods^ section. The study did not in-
clude animals; therefore, issues relating to animal welfare do not apply.
Conflict of interest The author declares that he has no conflict of
interest.
References
1. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach
C, Stahmer I , Klo th S , Brand t E , F lad HD (1991)
Immunobiochemical and molecular biologic characterization of
the cell proliferation-associated nuclear antigen that is defined by
monoclonal antibody Ki-67. Am J Pathol 138:867–873
2. van Diest PJ, der WE V, Baak JP (2004) Prognostic value of pro-
liferation in invasive breast cancer: a review. J Clin Pathol 57:675–
681
3. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA
(2010) Ki67 in breast cancer: prognostic and predictive potential.
Lancet Oncol 11:174–183
4. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B,
Senn HJ (2009) Panel members (2009) thresholds for therapies:
highlights of the St Gallen International Expert Consensus on the
primary therapy of early breast cancer. Ann Oncol 20:1319–1329
5. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B,
Senn HJ, Panel members (2011) Strategies for subtypes—dealing
with the diversity of breast cancer: highlights of the St. Gallen
International Expert Consensus on the Primary Therapy of Early
Breast Cancer 2011. Ann Oncol 22:1736–1747
6. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart
M, Thürlimann B, Senn HJ (2013) Panel members (2013) person-
alizing the treatment of women with early breast cancer: highlights
of the St Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer. Ann Oncol 24:2206–2223
7. Gándara-Cortes M, Vázquez-Boquete Á, Fernández-Rodríguez B,
Viaño P, Ínsua D, Seoane-Seoane A, Gude F, Gallego R, Fraga M,
Antúnez JR, Curiel T, Pérez-López E, García-Caballero T (2018)
Breast cancer subtype discrimination using standardized 4-IHC and
digital image analysis. Virchows Arch 472:195–203. https://doi.
org/10.1007/s00428-017-2194-z
8. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC,
Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, Mcshane L,
Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou
C, Smith IE, Viale G, Zujewski JA, Hayes DF, International Ki-67
in Breast Cancer Working Group (2011) Assessment of Ki67 in
breast cancer: recommendations from the International Ki67 in
Breast Cancer working group. J Natl Cancer Inst 103:1656–1664
9. Laenkholm AV, Grabau D, Møller Talman ML, Balslev E, Bak
Jylling AM, Tabor TP, Johansen M, Brügmann A, Lelkaitis G, Di
Caterino T, Mygind H, Poulsen T, Mertz H, Søndergaard G, Bruun
Rasmussen B (2018) An inter-observer Ki67 reproducibility study
applying two different assessment methods: on behalf of the Danish
Scientific Committee of Pathology, Danish breast cancer coopera-
tive group (DBCG). Acta Oncol 57:83–89
10. Cserni G, Kulka J, Francz M, Járay B, Kálmán E, Kovács I,
Krenács T, Udvarhelyi N, Vass L (2016) Pathological diagnosis,
work-up and reporting of breast cancer. Recommendations of the
3rd Hungarian Consensus Conference on Breast Cancer. Magy
Onkol 60:209–228
11. Hirokawa M, Carney JA (2000) Cell membrane and cytoplasmic
staining for MIB-1 in hyalinizing trabecular adenoma of the thyroid
gland. Am J Surg Pathol 24:575–578
152 Virchows Arch (2018) 473:145–153
12. Hattori H (2002) Sclerosing haemangioma of the lung is positive
for MIB-1 in cell membrane and cytoplasmic staining pattern.
Histopathology 40:291–293
13. Leonardo E, Volante M, Barbareschi M, Cavazza A, Dei Tos AP,
Bussolati G, Papotti M (2007) Cell membrane reactivity of MIB-1
antibody to Ki67 in human tumors: fact or artifact? Appl
Immunohistochem Mol Morphol 15:220–223
14. Faratian D, Munro A, Twelves C, Bartlett JM (2009) Membranous
and cytoplasmic staining of Ki67 is associated with HER2 and ER
status in invasive breast carcinoma. Histopathology 54:254–257
15. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske
A, Obermann E, Ohlschlegel C, Padberg B, Rakozy C, Sancho
Oliver S, Schobinger-Clement S, Schreiber-Facklam H, Singer G,
Tapia C, Wagner U, Mastropasqua MG, Viale G, Lehr HA (2012)
How reliable is Ki-67 immunohistochemistry in grade 2 breast car-
cinomas? A QA study of the Swiss Working Group of Breast- and
Gynecopathologists. PLoS One 7:e37379
16. Cserni G, Vörös A, Liepniece-Karele I, Bianchi S, Vezzosi V,
Grabau D, Sapino A, Castellano I, Regitnig P, Foschini MP,
Zolota V, Varga Z, Figueiredo P, Decker T, Focke C, Kulka J,
Kaya H, Reiner-Concin A, Amendoeira I, Callagy G, Caffrey E,
Wesseling J, Wells C (2014) Distribution pattern of the Ki67 label-
ling index in breast cancer and its implications for choosing cut-off
values. Breast 23:259–263
17. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL,
Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M,
Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K,
Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz
JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G,
Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC
(2010) American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for immunohis-
tochemical testing of estrogen and progesterone receptors in breast
cancer. Arch Pathol Lab Med 134:e48–e72
18. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J,
Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO,
National Coordinating Committee for Breast Pathology (2015)
Updated UK recommendations for HER2 assessment in breast can-
cer. J Clin Pathol 68:93–99
19. Cserni G, Chmielik E, Cserni B, Tot T (2018) The new TNM-based
staging of breast cancer. Virchows Arch. https://doi.org/10.1007/
s00428-018-2301-9
20. Cserni G (2014) Reversed polarity of the glandular epithelial cells
in micropapillary carcinoma of the large intestine and the EMA/
MUC1 immunostain. Pathology 46:527–532
21. Niemiec J, Adamczyk A, Ambicka A,Mucha-Małecka A,Wysocki
WM, Majchrzyk K, Ryś J (2015) BGX-Ki-67 index as a supple-
mentary marker to MIB-1 index, enabling more precise distinction
between luminal A and B subtypes of breast carcinoma and elimi-
nating the problem of membranous/cytoplasmic MIB-1 staining.
Am J Clin Pathol 143:419–429
22. Kővári B, Báthori Á, Cserni G (2015) CD10 immunohistochemical
expression in apocrine lesions of the breast. Pathobiology 82:259–263
23. https://www.ncbi.nlm.nih.gov/protein (Accessed 03 Mar 2018)
24. Ács B, Kulka J, Kovács KA, Teleki I, Tőkés AM, Meczker Á,
Győrffy B, Madaras L, Krenács T, Szász AM (2017) Comparison
of 5 Ki-67 antibodies regarding reproducibility and capacity to
predict prognosis in breast cancer: does the antibody matter? Hum
Pathol 65:31–40
25. Niemiec JA, Adamczyk A, Małecki K, Majchrzyk K, Ryś J (2012)
Relationships between immunophenotype, Ki-67 index, microvas-
cular density, Ep-CAM/P-cadherin, and MMP-2 expression in
early-stage invasive ductal breast cancer. Appl Immunohistochem
Mol Morphol 20:550–560
26. Wang D, Pang Z, Clarke GM, Nofech-Mozes S, Liu K, Cheung
AM, Filkins RJ, Yaffe MJ (2016) Ki-67 membranous staining: bi-
ologically relevant or an artifact of multiplexed immunofluorescent
staining. Appl Immunohistochem Mol Morphol 24:447–452
Virchows Arch (2018) 473:145–153 153
